截至本公告披露日，蒋海洪先生未持有公司股份，不存在应当履行而未履行的 承诺事项。 蒋海洪先生在公司任职期间勤勉尽责、认真履行各项职责，推动公司规范运作， 公司董事会对蒋海洪先生为公司的发展所作出的贡献表示衷心的感谢。 证券代码：300453 证券简称：三鑫医疗 公告编号：2025-067 江西三鑫医疗科技股份有限公司 关于独立董事任期将满六年辞职的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、独立董事辞职的情况 江西三鑫医疗科技股份有限公司（以下简称"公司"）董事会于近日收到独立 董事蒋海洪先生的书面辞职报告。蒋海洪先生自 2019 年 12 月 26 日起担任公司独立 董事，根据《上市公司独立董事管理办法》《公司章程》等相关规定，独立董事连 续任职不得超过六年。蒋海洪先生因连续担任公司独立董事将满六年，申请辞去公 司独立董事及薪酬与考核委员会主任委员职务，辞职后将不再担任公司及控股子公 司任何职务。 鉴于蒋海洪先生辞职将导致公司独立董事人数不足董事会人数的三分之一，专 门委员会中独立董事所占比例不符合法律法规及《公司章程》要求独立董事应当过 半数并担任 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-068 江西三鑫医疗科技股份有限公司 关于补选第五届董事会独立董事的公告 1、第五届董事会第二十三次会议决议； 2、第五届董事会第四次独立董事专门会议决议； 3、独立董事资格证书； 4、深圳证券交易所要求的其他文件。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、补选独立董事的情况 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日召 开第五届董事会第二十三次会议，审议通过了《关于补选第五届董事会独立董事的 议案》，经公司独立董事专门会议资格审查，董事会同意提名刘冬京女士为公司第 五届董事会独立董事候选人（简历详见附件），任期自公司 2025 年第二次临时股东 会审议通过之日起至第五届董事会任期届满之日止。刘冬京女士当选后将担任公司 第五届董事会薪酬与考核委员会主任委员（召集人）职务，任期至第五届董事会任 期届满之日止。 刘冬京女士已取得上海证券交易所独立董事资格证书，任职生效后将根据相关 规定及时参加深圳证券交易所组织的有关培训。 刘冬京女士的独立董事候选人任职 ...

1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 证券代码：300453 证券简称：三鑫医疗 公告编号：2025-070 江西三鑫医疗科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 3、会议召开的合法、合规性：经公司第五届董事会第二十三次会议审议 通过，决定召开 2025 年第二次临时股东会，本次会议的召集、召开符合《中 华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政 法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 26 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 12 月 26 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2025 年 12 月 26 日 9 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-066 江西三鑫医疗科技股份有限公司 关于股东减持股份期限届满暨实施情况的公告 1、股东减持股份情况 | 股东 | 减持 | 减持期间 | 减持均价 | 减持股数 | 占总股本的 | | --- | --- | --- | --- | --- | --- | | 名称 | 方式 | | （元/股） | （股） | 比例（%） | | 彭九莲 | 集中 竞价 | 2025年10月10日-2025年10月22日 | 9.22 | 726,800 | 0.1392% | | | | 2025年10月31日-2025年11月26日 | 9.71 | 1,537,600 | 0.2946% | | | | 合计 | 9.51 | 2,264,400 | 0.4328% | 注：（1）减持股份来源：首次公开发行前已持有的股份（含该等股份首次公开发行后因 资本公积转增股本而相应增加的股份）。 （2）截至本公告披露日，公司回购专用证券账户中的股份数量为160,000股，上表在计算 占总股本比例时，总股本已剔除公司回购专用证券账户中的股份数量，下同。 （3）公司于 ...

Core Viewpoint - The article emphasizes the dual transformation of technology and industry in the global economy, highlighting the significant growth potential of small and medium-sized listed companies in China as they contribute to industrial upgrades and innovation in the capital market [1][5]. Group 1: Event Overview - The "Future 20 · 2025 A-Share Listed Companies Growth Power Annual Conference" was successfully held in Shanghai, focusing on the transformation of China's economic structure and the growth potential of small and medium-sized listed companies [1][3]. - The event was co-hosted by prominent organizations including Yicai Media, Ernst & Young (China), and others, utilizing a proprietary growth assessment model to evaluate and select 20 companies with the highest growth potential based on 12 dimensions and 38 indicators [3][4]. Group 2: Government and Economic Insights - The Deputy District Mayor of Jiading, Lu Zufang, stated that small and medium-sized enterprises are crucial for economic resilience and a source of vitality for national technological innovation [5][6]. - Jiading District is focusing on key industries such as smart connected vehicles, integrated circuits, and biomedicine, while also exploring emerging fields like quantum technology and new energy [6][10]. Group 3: Industry Development and Future Outlook - The conference highlighted the importance of high-quality development in China's economy, particularly in 2025, as a pivotal year for structural upgrades and the A-share market's transition to high-quality growth [6][9]. - Experts discussed the need for companies to balance global expansion with enhancing new productive forces, emphasizing the role of technological innovation in driving growth [12][18]. Group 4: Selected Companies and Recognition - The 20 companies recognized for their growth potential include Huaming Equipment, Jack Technology, and others, reflecting their past achievements and future growth expectations [24][27]. - The selection process aimed to identify companies with high technological content, growth potential, and sound governance, contributing to the narrative of China's industrial upgrade [38]. Group 5: Investment Perspectives - Investment professionals emphasized the importance of understanding the growth potential of small and medium-sized companies, which can offer significant opportunities compared to larger blue-chip firms [36][37]. - The need for a multi-dimensional investment logic was highlighted, encouraging investors to engage deeply with companies to uncover hidden growth potential [36][37].

Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]

Core Insights - Sanxin Medical has successfully transformed from traditional infusion and injection fields to the blood purification sector, becoming a significant player in the industry with a strong growth trajectory [3][4][5]. Group 1: Company Transformation and Growth - Sanxin Medical's net profit has shown a compound annual growth rate (CAGR) of 29.82% over the past five years, indicating robust growth momentum [3]. - The company has shifted its revenue structure, with blood purification products' revenue share increasing from 20% in 2015 to 81% in 2024, reflecting a successful business transformation [5]. - Total revenue has grown from 312 million yuan in 2015 to 1.5 billion yuan in 2024, achieving a CAGR of 19.07% [5]. Group 2: Product Development and Innovation - Sanxin Medical has developed a comprehensive product line in blood purification, including dialysis tubes and related products, leveraging its technical expertise from the infusion sector [4][6]. - The company has established the first domestic assembly production line for dialysis devices, enhancing its manufacturing capabilities and reducing costs by over 30% [6]. - The firm is working on domestic production technology for medical-grade polyethersulfone (PES), which is crucial for dialysis membranes, aiming to reduce reliance on imports [7]. Group 3: Global Expansion and Market Strategy - Sanxin Medical's overseas revenue reached 274 million yuan in 2024, marking a 39.70% increase, and is projected to grow further, constituting 25% of total revenue in the first half of 2025 [8]. - The company has registered products in countries like Indonesia and Peru, and is advancing certification processes in Turkey and Vietnam, enhancing its global competitiveness [8]. - Sanxin Medical aims to lead the health industry while contributing to the well-being of its employees and society, with a vision of becoming a century-old enterprise [9].

Group 1: Jiangzhong Pharmaceutical - Jiangzhong Pharmaceutical's flagship product, Jianwei Digestive Tablets, has achieved cumulative sales of over 5 billion boxes and has been the top-selling OTC digestive medicine in China for 21 consecutive years [20][21] - The company aims to enhance quality through innovation, focusing on three main business areas: OTC products, health consumer goods, and prescription drugs, achieving a compound annual growth rate (CAGR) of 16% in revenue and 13% in net profit during the 14th Five-Year Plan period [20][21] - The company has implemented smart manufacturing technologies, achieving over 95% automation in its production processes, significantly improving efficiency and reducing labor costs [22][23] Group 2: Technological Innovation - Jiangzhong Pharmaceutical has developed a unique MVR concentration technology that enhances the extraction efficiency of active ingredients from traditional Chinese medicine to over 90% [22] - The company has established a national key laboratory for modern Chinese medicine creation, focusing on the innovative transformation of classic formulas into modern products [24] - The introduction of innovative flavors and purification techniques has transformed traditional herbal medicines into more palatable products, appealing to a broader consumer base [25] Group 3: Cultural Integration and Market Expansion - Jiangzhong Pharmaceutical has launched a "Healthy Hot Pot" concept that incorporates traditional medicinal ingredients, aiming to modernize and popularize traditional Chinese medicine among younger consumers [26][27] - The company plans to continue expanding its cultural outreach and application of traditional Chinese medicine through various channels, including tourism and dining [27] Group 4: Fushite Company - Fushite has positioned itself in the hydraulic pipeline sector, with a strategic focus on the mining after-market, anticipating a market size of $19.33 billion by 2030 [28][30] - The company has established a comprehensive service system that includes industrial maintenance and heavy spare parts supply, expanding its service capabilities beyond just hydraulic pipeline repairs [32] Group 5: Naipu Mining Machinery - Naipu Mining Machinery has developed a global service network covering over 50 countries, focusing on wear-resistant materials and mining machinery [34][36] - The company has successfully transitioned from basic spare parts production to advanced wear-resistant materials, leveraging new material technologies to enhance product performance [35][36] - Naipu's international strategy includes establishing production bases in Peru to meet the growing demand for mining equipment and spare parts in South America [39][40] Group 6: Sanxin Medical - Sanxin Medical has transformed from a traditional infusion and injection company to a significant player in the blood purification medical device sector, achieving a CAGR of 29.82% in net profit over the past five years [42][45] - The company has expanded its product offerings in blood purification, with revenue from this segment increasing from 20% in 2015 to 81% in 2024 [45] - Sanxin Medical is actively pursuing global market expansion, with overseas revenue growing by 39.70% in 2024, indicating a strong international presence [48][49]

Group 1 - The core viewpoint of the news is that Sanxin Medical has seen a stock price increase of 5.07%, reaching 10.36 CNY per share, with a trading volume of 1.22 billion CNY and a turnover rate of 3.39%, resulting in a total market capitalization of 54.09 billion CNY [1] - Sanxin Medical, established on March 7, 1997, and listed on May 15, 2015, specializes in the research, manufacturing, sales, and service of medical devices, with its main revenue sources being blood purification (82.23%), drug delivery devices (10.83%), thoracic surgery (4.60%), and others (2.34%) [1] Group 2 - From the perspective of major circulating shareholders, a fund under Dacheng Fund has entered the top ten circulating shareholders of Sanxin Medical, holding 2.7326 million shares, which accounts for 0.76% of the circulating shares [2] - The Dacheng Growth Mixed Fund A (160926) has achieved a year-to-date return of 26.07% and a one-year return of 19.24%, ranking 3476 out of 8147 and 3487 out of 8056 respectively [2] - The fund manager, Zou Jian, has been in the position for 4 years and 292 days, with a total fund asset size of 1.212 billion CNY and a best return of 14.09% during his tenure [2] Group 3 - The Dacheng Growth Mixed Fund A (160926) has increased its holdings in Sanxin Medical by 150,000 shares in the third quarter, making it the eighth largest holding in the fund, which represents 3.23% of the fund's net value [3] - The fund has also realized a floating profit of approximately 1.3663 million CNY from its investment in Sanxin Medical [3]